Abstract
Discussion Forum (0)
Introduction: Alkaline phosphatase (ALP) is produced by placental syncytiotrophoblasts and levels are normally increased in pregnancy. The aim was to determine if total ALP level between 24-28 weeks could be used as a screening tool in healthy singleton pregnancies as a predictor for low birth weight.
Methods: An IRB approved prospective study with total ALP serum levels collected from women with a singleton pregnancy between 24-28 weeks gestation. Pregnancies complicated by conditions that could affect ALP levels or fetal growth were ineligible. Pregnancy and birth data was abstracted from the patient's chart. Infants were classified as SGA, AGA and LGA by gestational age at birth and gender.
Results: 255 patients had complete ALP level and delivery outcome data. There were no statistically significant differences in baseline maternal demographic characteristics noted between groups. Mean gestational age at delivery was 39.1 weeks. ALP levels in the SGA group, 83(±35) IU/L, were not significantly higher when compared to the AGA group, 69(±21) (p=0.062), and LGA group was 78(± 21)IU/L. Mean birth weights for SGA, AGA and LGA were 2609(±282), 3247(±486), and 4118(±290)gm. Mothers of SGA infants had lower GCT results at 94.9(±23.4)mg/dL as compared to mothers of AGA infants 107.6(±25.5), p=0.016. Patients who developed gestational hypertension were more likely to have ALP levels > 75th% (p=0.002).
Conclusion/Implications: There was only a weak association noted between ALP levels at 24 to 28 weeks gestation in healthy singleton pregnancies and birthweight. Therefore, ALP performs poorly as a way to screen for SGA growth in newborns
Methods: An IRB approved prospective study with total ALP serum levels collected from women with a singleton pregnancy between 24-28 weeks gestation. Pregnancies complicated by conditions that could affect ALP levels or fetal growth were ineligible. Pregnancy and birth data was abstracted from the patient's chart. Infants were classified as SGA, AGA and LGA by gestational age at birth and gender.
Results: 255 patients had complete ALP level and delivery outcome data. There were no statistically significant differences in baseline maternal demographic characteristics noted between groups. Mean gestational age at delivery was 39.1 weeks. ALP levels in the SGA group, 83(±35) IU/L, were not significantly higher when compared to the AGA group, 69(±21) (p=0.062), and LGA group was 78(± 21)IU/L. Mean birth weights for SGA, AGA and LGA were 2609(±282), 3247(±486), and 4118(±290)gm. Mothers of SGA infants had lower GCT results at 94.9(±23.4)mg/dL as compared to mothers of AGA infants 107.6(±25.5), p=0.016. Patients who developed gestational hypertension were more likely to have ALP levels > 75th% (p=0.002).
Conclusion/Implications: There was only a weak association noted between ALP levels at 24 to 28 weeks gestation in healthy singleton pregnancies and birthweight. Therefore, ALP performs poorly as a way to screen for SGA growth in newborns
Introduction: Alkaline phosphatase (ALP) is produced by placental syncytiotrophoblasts and levels are normally increased in pregnancy. The aim was to determine if total ALP level between 24-28 weeks could be used as a screening tool in healthy singleton pregnancies as a predictor for low birth weight.
Methods: An IRB approved prospective study with total ALP serum levels collected from women with a singleton pregnancy between 24-28 weeks gestation. Pregnancies complicated by conditions that could affect ALP levels or fetal growth were ineligible. Pregnancy and birth data was abstracted from the patient's chart. Infants were classified as SGA, AGA and LGA by gestational age at birth and gender.
Results: 255 patients had complete ALP level and delivery outcome data. There were no statistically significant differences in baseline maternal demographic characteristics noted between groups. Mean gestational age at delivery was 39.1 weeks. ALP levels in the SGA group, 83(±35) IU/L, were not significantly higher when compared to the AGA group, 69(±21) (p=0.062), and LGA group was 78(± 21)IU/L. Mean birth weights for SGA, AGA and LGA were 2609(±282), 3247(±486), and 4118(±290)gm. Mothers of SGA infants had lower GCT results at 94.9(±23.4)mg/dL as compared to mothers of AGA infants 107.6(±25.5), p=0.016. Patients who developed gestational hypertension were more likely to have ALP levels > 75th% (p=0.002).
Conclusion/Implications: There was only a weak association noted between ALP levels at 24 to 28 weeks gestation in healthy singleton pregnancies and birthweight. Therefore, ALP performs poorly as a way to screen for SGA growth in newborns
Methods: An IRB approved prospective study with total ALP serum levels collected from women with a singleton pregnancy between 24-28 weeks gestation. Pregnancies complicated by conditions that could affect ALP levels or fetal growth were ineligible. Pregnancy and birth data was abstracted from the patient's chart. Infants were classified as SGA, AGA and LGA by gestational age at birth and gender.
Results: 255 patients had complete ALP level and delivery outcome data. There were no statistically significant differences in baseline maternal demographic characteristics noted between groups. Mean gestational age at delivery was 39.1 weeks. ALP levels in the SGA group, 83(±35) IU/L, were not significantly higher when compared to the AGA group, 69(±21) (p=0.062), and LGA group was 78(± 21)IU/L. Mean birth weights for SGA, AGA and LGA were 2609(±282), 3247(±486), and 4118(±290)gm. Mothers of SGA infants had lower GCT results at 94.9(±23.4)mg/dL as compared to mothers of AGA infants 107.6(±25.5), p=0.016. Patients who developed gestational hypertension were more likely to have ALP levels > 75th% (p=0.002).
Conclusion/Implications: There was only a weak association noted between ALP levels at 24 to 28 weeks gestation in healthy singleton pregnancies and birthweight. Therefore, ALP performs poorly as a way to screen for SGA growth in newborns
{{ help_message }}
{{filter}}